Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
ID: 356687Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356687

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-25-123.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for epidemiologic research on emerging risk factors associated with liver cancer in the United States, specifically through the R21 Clinical Trial Not Allowed mechanism. This initiative aims to explore innovative hypotheses regarding biological, environmental, and social risk factors, while excluding applications focused solely on viral hepatitis as the etiologic factor. The research is crucial for informing prevention strategies and addressing the rising rates of liver cancer, particularly hepatocellular carcinoma, among various U.S. populations. Interested applicants can apply for a budget of up to $275,000 over two years, with the application process opening on January 16, 2025, and the submission deadline set for May 7, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-25-123.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-25-123.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) for epidemiologic research focused on emerging risk factors for liver cancer in the United States. The program, operating under the R21 Exploratory/Developmental Research Grant mechanism, aims to explore innovative hypotheses regarding both biological and social risk factors contributing to liver cancer, including hepatocellular carcinoma and other histological subtypes. The application process opens on January 16, 2025, with a budget limit of $275,000 for two years. Applicants are encouraged to leverage existing resources and conduct collaborative research that includes data on non-viral factors such as obesity and metabolic syndrome. Research areas of interest include the interactions of multiple risk factors, the impact of behavioral and social determinants, and novel hypotheses about liver carcinogenesis. The NOFO specifically excludes applications focused solely on viral hepatitis as the etiologic factor. The initiative aims to inform prevention strategies and address increasing liver cancer rates in various U.S. populations.
    Similar Opportunities
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant focused on epidemiologic research related to liver cancer susceptibility and emerging risk factors. This funding opportunity aims to investigate both established risk factors, such as viral hepatitis, and novel influences, including environmental and social factors, that contribute to liver cancer incidence in the United States. The initiative underscores the increasing recognition of liver cancer's rising incidence and the need for targeted public health strategies, with a funding limit of $275,000 available over two years. Interested applicants must adhere to NIH guidelines and submit their applications by May 7, 2025; for further inquiries, they can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for epidemiologic research on emerging risk factors associated with liver cancer, specifically hepatocellular carcinoma and other subtypes. This initiative aims to investigate both novel and established biological, environmental, and social risk factors that contribute to liver cancer development in the United States, with a focus on understanding the interplay of these factors. The funding is available through the Research Project Grant (R01) mechanism for projects lasting up to five years, and applications are encouraged from a diverse range of eligible applicants, including educational institutions and community organizations. Interested parties should note that the application deadline is May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for epidemiologic research focused on emerging risk factors associated with liver cancer in the United States, specifically through the R01 grant mechanism. This initiative aims to investigate novel hypotheses regarding biological, environmental, and social factors, as well as their interactions with established risk factors like viral hepatitis, to better understand their role in the development of hepatocellular carcinoma and other liver cancer types. The program encourages applications that explore non-viral contributors, such as obesity and diabetes, and seeks to produce insights that will inform evidence-based strategies for liver cancer prevention and control. Interested applicants, including higher education institutions, nonprofit organizations, and foreign entities, must submit their proposals by February 5, 2025, and can find additional information at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Interventions to Address Disparities in Liver Diseases and Liver Cancer," aimed at supporting research interventions that target health disparities in liver diseases and liver cancer among marginalized populations in the United States. This initiative encourages researchers to propose multi-level and multi-domain approaches that address social determinants of health, with a focus on improving screening, treatment, and health outcomes for affected groups, including racial and ethnic minorities and individuals with lower socioeconomic status. The grant has no specific budget limit and allows for a maximum project period of five years, with applications accepted starting September 5, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address Disparities in Liver Diseases and Liver Cancer," aimed at supporting research initiatives that develop and test multi-level and multi-domain interventions to reduce health disparities related to liver diseases among marginalized populations in the United States. The initiative encourages applicants to design community-engaged and culturally sensitive approaches focusing on screening, prevention, treatment, and management of liver conditions, particularly targeting racial and ethnic minorities, individuals of low socioeconomic status, and those in underserved communities. This grant is crucial for addressing systemic issues that influence health access and outcomes, with applications due starting January 5, 2025, and a maximum project duration of five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" grant, aimed at enhancing research into the relationship between co-infections and cancer. This initiative encourages exploratory studies that investigate how concurrent or sequential infections by multiple pathogens influence carcinogenesis, with a focus on mechanistic and epidemiological insights rather than clinical trials. The grant supports research that may inform cancer prevention and treatment strategies, particularly concerning infection-related cancers, with a maximum award of $275,000 for a two-year project period. Applications are due starting January 16, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-083.html.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)" aimed at supporting interdisciplinary research to enhance public awareness and develop interventions that address the relationship between alcohol consumption and cancer risk. The initiative focuses on changing social norms, evaluating alcohol policy approaches, and implementing population-level interventions, particularly targeting underrepresented minority populations who experience disparities related to alcohol use and cancer. This funding opportunity is critical as alcohol is a significant preventable risk factor for various cancers, and traditional individual-level interventions have proven inadequate. Applications will be accepted starting January 5, 2025, with a maximum project period of five years, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. The application deadline is set for January 7, 2027.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.